here's that word again - imminent

ANALYST CORNER
Dr Reddy?s remains sector outperformer

Posted: Friday, Jun 10, 2011 at 2054 hrs IST


Despite FDA?s acceptance of Fondaparinux ANDA under priority review, delay in the launch of gArixtra has been a major disappointment. Since 26 months have already elapsed post filing of ANDA, we believe the launch is imminent (based on average review time of 27-30 months for non-prioritised generics). Potential upside for Dr Reddy?s Laboratories (DRL) from this opportunity could be significant (incremental EPS of R3.7/7.4 per share in FY12/13E) as it is likely to remain a limited competition opportunity for at least next two-three years.


http://www.financialexpress.com/news/dr-reddys-remains-sector-outperformer/801545/1